For immediate release |
6 March 2017 |
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Issue of Equity, Director/PDMR Shareholding and Total Voting Rights
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notices to exercise options over 129,729 ordinary shares in the Company including a notice from David Howat, a Person Discharging Managerial Responsibility.
The options were granted under The Evgen Pharma plc Long Term Incentive Plan and have an exercise price of nil pence per share. Accordingly, the Company has issued and allotted 129,729 new ordinary shares of 0.25 pence each ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 10 March 2017.
There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 73,272,591. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO www.evgen.com |
c/o +44 (0) 20 7466 5000 |
|
|
Buchanan Mark Court, Sophie Cowles, Stephanie Watson |
+44 (0) 20 7466 5000 |
|
|
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes and Rob Rees (Corporate Broking) |
+44 (0) 20 3861 6625 |
|
|
|
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its registered office at the Liverpool Science Park and its headquarters in Wilmslow, Cheshire, UK. Evgen Pharma joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information please visit: www.evgen.com
For a recent analyst research note on Evgen Pharma, please visit:
http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf
